← Leaderboards
Charles D. Smith
Pennsylvania State Univ Hershey Med Ctr
$6,000,152
Attributed
$6,077,912
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $705.7K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$6,077,912 · 6
By mechanism
R01$4,404,952 · 4
R24$1,517,440 · 1
R03$155,520 · 1
Top collaborators
- Lorne J Hofseth2 shared
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Karam E El-Bayoumy$14,292,983
- Vladimir S. Spiegelman$6,129,643
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellAcyltransferaseInhibitor/AntagonistCellsMediatingAntineoplastic AgentsTherapeutic AgentsApoptosisDrug Discovery /IsolationCell ProliferationTumorEnzyme InhibitorsAnti-Cancer TherapeuticIn VivoIn VitroDrug Screening /EvaluationSphingosine KinaseSphingolipidsSphingosine 1-PhosphateMetabolismNeoplasm /Cancer PharmacologyKinase InhibitorMalignant NeoplasmsAntineoplastics
Grant awards (26)
Sphingosine Kinase as a Target for Cancer Therapy$269,078
R01 · FY2011 · CA · contact PI
Sphingosine Kinase as a Target for Cancer Therapy$277,400
R01 · FY2010 · CA · contact PI
Sphingosine Kinase as a Target for Cancer Therapy$277,400
R01 · FY2009 · CA · contact PI
Acyltransferase Inhibitors as Anti Ras Agents$235,339
R01 · FY2009 · CA · contact PI
Sphingosine Kinase as a Target for Cancer Chemoprevention$74,909
R03 · FY2009 · CA
Sphingosine Kinase as a Target for Cancer Therapy$277,400
R01 · FY2008 · CA · contact PI
Acyltransferase Inhibitors as Anti Ras Agents$235,339
R01 · FY2008 · CA · contact PI
Sphingosine Kinase as a Target for Cancer Chemoprevention$80,611
R03 · FY2008 · CA
Sphingosine Kinase as a Target for Cancer Therapy$277,400
R01 · FY2007 · CA · contact PI
Acyltransferase Inhibitors as Anti Ras Agents$235,339
R01 · FY2007 · CA · contact PI
Acyltransferase Inhibitors as Anti Ras Agents$242,367
R01 · FY2006 · CA · contact PI
DRUG DISCOVERY CORE FACILITY$307,800
R24 · FY2005 · CA
Acyltransferase Inhibitors as Anti Ras Agents$248,163
R01 · FY2005 · CA
Drug Discovery for Diabetic Retinopathy$115,163
R01 · FY2005 · EY
Drug Discovery for Diabetic Retinopathy$34,537
R01 · FY2005 · EY
DRUG DISCOVERY CORE FACILITY$307,800
R24 · FY2004 · CA
Acyltransferase Inhibitors as Anti Ras Agents$255,474
R01 · FY2004 · CA
Drug Discovery for Diabetic Retinopathy$149,700
R01 · FY2004 · EY
DRUG DISCOVERY CORE FACILITY$307,800
R24 · FY2003 · CA
Acyltransferase Inhibitors as Anti Ras Agents$255,474
R01 · FY2003 · CA
DRUG DISCOVERY CORE FACILITY$297,020
R24 · FY2002 · CA
Acyltransferase Inhibitors as Anti Ras Agents$224,906
R01 · FY2002 · CA
DRUG DISCOVERY CORE FACILITY$297,020
R24 · FY2001 · CA
NOVEL COMPOUNDS WHICH CIRCUMVENT MULTIDRUG RESISTANCE$273,482
R01 · FY2001 · CA
Acyltransferase Inhibitors as Anti Ras Agents$255,474
R01 · FY2001 · CA
NOVEL COMPOUNDS WHICH CIRCUMVENT MULTIDRUG RESISTANCE$265,517
R01 · FY2000 · CA